II. Claim Amendments

1. (Currently Amended) An i~~I~~mmunogenic composition comprising a fusion protein and a saponin adjuvant, characterized in that the fusion protein comprises a heterologous hydrophobic peptide which is fused to the N-terminus and/or to the C-terminus of a core polypeptide, the core polypeptide comprising at least one protective epitope, the saponin adjuvant being in a free form.

2. (Currently Amended) The i~~I~~mmunogenic composition according to Celaim 1, characterized in that the core polypeptide is a component of a protein of an organism of the phylum Apicomplexa.

3. (Currently Amended) The i~~I~~mmunogenic composition according to Celaim 2, characterized in that the core polypeptide is a component of a protein of an organism of the Piroplasmida or of the class Coccidia.

4. (Currently Amended) The i~~I~~mmunogenic composition according to Celaim 3, characterized in that the core polypeptide is a component of a protein of an organism of the genera Eimeria or Babesia.

5. (Currently Amended) The i~~I~~mmunogenic composition according to Claim 1 ~~any one of claims 1 to 4~~, characterized in that the heterologous hydrophobic peptide is from an N-terminal hydrophobic sequence.

6. (Currently Amended) The i~~I~~mmunogenic composition according to Claim 1 any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an internal hydrophobic sequence.

7. (Currently Amended) The i~~I~~mmunogenic composition according to Claim 1 ~~any one of claims 1 to 4~~, characterized in that the heterologous hydrophobic peptide is from a C-terminal hydrophobic sequence.

8. (Currently Amended) The i~~I~~mmunogenic composition according to Celaim 7, characterized in that the C-terminal hydrophobic sequence is from decay accelerating factor (DAF).

9. (Currently Amended) The i~~I~~mmunogenic composition according to Claim 1 ~~any one of claims 1 to 8~~, characterized in that the saponin adjuvant is Quillaja saponin.

10. (Currently Amended) A v~~V~~accine characterized in that it comprises an immunogenic composition according to Claim 1 ~~any one of claims 1 to 9~~ and a pharmaceutically acceptable carrier.

11. (Currently Amended) The v~~V~~ accine according to Celaim 10, characterized in that it comprises at least one additional immunoactive component.

12. (Currently Amended) The v~~V~~ accine according Claim 10 ~~to either one of claims 10 or 11~~, characterized in that it is in a freeze-dried form.

13. (Currently Amended) The m~~M~~ethod for the preparation of a vaccine according to claim 10, characterized in that the method comprises admixing an immunogenic composition according to ~~any one of claims 1 to 9~~ Claim 1 and a pharmaceutically acceptable carrier.

14. (Cancelled, without prejudice or disclaimer)